Ascites
📧 Sign up to get email alerts when something new happens for Ascites.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-05-07Clinical Trial Update: Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis. [NA]
A clinical trial evaluating midodrine for refractory or recurrent ascites in children with cirrhosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2019-06-14Clinical Trial Update: Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis [Phase 4]
A Phase 4 trial evaluating fresh frozen plasma as a substitute for albumin in patients undergoing large volume paracentesis has been withdra…
-
EMA withdrawal · 2017-07-12EMA Withdrawn: Removab (catumaxomab) — Neovii Biotech GmbH
Removab (catumaxomab) has been withdrawn from the market by Neovii Biotech GmbH.
-
CLINICAL_TRIALS withdrawal · 2016-01-15Clinical Trial Update: Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects [Phase 2]
A Phase 2 trial comparing eplerenone with spironolactone for ascites due to liver cirrhosis has been withdrawn from further study.
-
CLINICAL_TRIALS withdrawal · 2015-08-04Clinical Trial Update: The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis
A study investigating the impact of large-volume paracentesis on fatigue, sleep, and quality of life in cirrhosis has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2013-07-31Clinical Trial Update: Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis [NA]
A clinical trial evaluating the effect of midodrine on portal pressures in patients with cirrhosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-05Clinical Trial Update: Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients [Phase 4]
A Phase 4 clinical trial examining lipopolysaccharide binding protein and infectious events in cirrhotic patients has been withdrawn.